BACE1 inhibitors
US-10723729-B2 · Jul 28, 2020 · US
US11034687B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11034687-B2 |
| Application number | US-202016903616-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 17, 2020 |
| Priority date | Mar 20, 2015 |
| Publication date | Jun 15, 2021 |
| Grant date | Jun 15, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
Opening claim text (preview).
The invention claimed is: 1. A compound of formula I: wherein: A is isoxazolyl or triazolyl; B is a heteroaryl group; R 1 is selected from the group consisting of i) C 1-6 -alkyl and ii) halogen-C 1-6 -alkyl; R 2 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; or R 1 and R 2 form together with the C-atom they are attached to, a C 3-6 -cycloalkyl-, wherein the C 3-6 -cycloalkyl- is optionally substituted by one or more substituents selected from the group consisting of halogen and hydroxyl; R 3 is selected from the group consisting of i) hydrogen, ii) C 3-6 -cycloalkyl, iii) halogen-C 1-6 -alkyl, and iv) C 1-6 -alkyl; R 4 is selected from the group consisting of i) hydrogen, and ii) C 1-6 -alkyl; R 5 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; R 6 is halogen; and R 7 is selected from the group consisting of i) amino, ii) cyano, iii) hydrogen, iv) OH, v) halogen, vi) C 1-6 -alkyl, vii) C 1-6 -alkyl-C 3-6 -cycloalkyl, viii) halogen-C 1-6 -alkyl, ix) C 1-6 -alkoxy-C 1-6 -alkyl, x) C 2-6 -alkynyl, xi) C 2-6 -alkynyl-C 1-6 -alkyl, xii) C 2-6 -alkynyl-C 1-6 -alkoxy xiii) C 1-6 -alkoxy, and xiv) halogen-C 1-6 -alkoxy; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 , which is of formula Ia, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is as defined in claim 1 : or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 , wherein B is a 6-membered heteroaryl group. 4. The compound according to claim 1 , wherein B is pyrazinyl, pyrimidinyl or pyridinyl. 5. The compound according to claim 1 , wherein R 1 is C 1-6 -alkyl. 6. The compound according to claim 1 , wherein R 1 is methyl. 7. The compound according to claim 1 , wherein R 2 is C 1-6 -alkyl. 8. The compound according to claim 1 , wherein R 2 is methyl. 9. The compound according to claim 1 , wherein R 1 and R 2 form together with the C-atom they are attached to a C 3-6 -cycloalkyl-. 10. The compound according to claim 1 , wherein R 1 and R 2 form together with the C-atom they are attached to a cyclopentyl. 11. The compound according to claim 1 , wherein R 3 is H, CH 3 , CD 3 , CH 2 CF 3 or cyclopropyl. 12. The compound according to claim 1 , wherein R 3 is C 1-6 -alkyl. 13. The compound according to claim 1 , wherein R 3 is methyl. 14. The compound according to claim 1 , wherein R 4 is hydrogen. 15. The compound according to claim 1 , wherein R 5 is C 1-6 -alkyl or halogen-C 1-6 -alkyl. 16. The compound according to claim 1 , wherein R 5 is methyl or —CH 2 F. 17. The compound according to claim 1 , wherein R 6 is F. 18. The compound according to claim 1 , wherein R 7 is Br, CH 2 -cyclopropyl, Cl, CN, Et, Me, OCH 2 CF 2 CHF 2, OCH 2 CF 3, OCH 2 CHF 2, OH or OMe.
containing three or more hetero rings · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Non-condensed thiazines containing further heterocyclic rings · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.